LP
ALNY icon

LMR Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

LMR Partners’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$24.7M Buy
74,661
+15,639
+26% +$5.32M 0.05% 181
2025
Q4 		$23.5M Buy
+59,022
New +$26.1M 0.04% 181
2025
Q2 		– Sell
-9,000
Closed -$2.43M – 1361
2025
Q1 		$2.43M Sell
9,000
-2,901
-24% -$746K 0.02% 629
2024
Q4 		$2.8M Sell
11,901
-55,588
-82% -$14.6M 0.02% 516
2024
Q3 		$18.6M Buy
67,489
+58,518
+652% +$15.2M 0.15% 124
2024
Q2 		$2.18M Sell
8,971
-62,400
-87% -$9.85M 0.02% 528
2024
Q1 		$10.7M Buy
71,371
+43,171
+153% +$7.2M 0.11% 174
2023
Q4 		$5.4M Sell
28,200
-39,524
-58% -$6.73M 0.06% 290
2023
Q3 		$12M Buy
67,724
+33,029
+95% +$6.3M 0.13% 167
2023
Q2 		$6.59M Buy
34,695
+13,551
+64% +$2.69M 0.07% 226
2023
Q1 		$4.24M Buy
+21,144
New +$4.44M 0.07% 300
2022
Q4 		– Sell
-4,107
Closed -$822K – 1100
2022
Q3 		$822K Sell
4,107
-134,266
-97% -$25.6M 0.02% 785
2022
Q2 		$20.2M Buy
138,373
+46,259
+50% +$6.56M 0.34% 58
2022
Q1 		$15M Buy
92,114
+69,886
+314% +$10.6M 0.17% 124
2021
Q4 		$3.77M Buy
+22,228
New +$4.13M 0.04% 301
2017
Q4 		– Sell
-50,588
Closed -$5.94M – 323
2017
Q3 		$5.94M Buy
+50,588
New +$4.32M 0.64% 33
2017
Q1 		– Sell
-86,245
Closed -$3.23M – 350
2016
Q4 		$3.23M Buy
+86,245
New +$3.61M 0.5% 33
2015
Q2 		– Sell
-58,889
Closed -$6.15M – 519
2015
Q1 		$6.15M Buy
+58,889
New +$5.97M 0.85% 26

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LMR Partners's ALNY Position: Q1 2026 in Review

LMR Partners increased its Alnylam Pharmaceuticals (ALNY) stake by 26% in Q1 2026, buying an estimated $5.32M and bringing the position to 74,661 shares worth $24.7M. The position accounts for 0.05% of the portfolio, ranked #181.

LMR Partners first reported a position in ALNY in Q1 2015 and has held it in 18 quarters since. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • LMR Partners held 74,661 shares of Alnylam Pharmaceuticals worth $24.7M as of Q1 2026.
  • LMR Partners bought 15,639 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $5.32M.
  • Alnylam Pharmaceuticals made up 0.05% of LMR Partners's portfolio in Q1 2026, its #181 holding.
  • LMR Partners first reported a position in Alnylam Pharmaceuticals in Q1 2015 and has held it in 18 quarters since.
  • 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on LMR Partners's 13F filing for Q1 2026, filed 15 May 2026.